368 related articles for article (PubMed ID: 25384535)
41. Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins.
Langenhan J; Dworschak J; Saschenbrecker S; Komorowski L; Schlumberger W; Stöcker W; Westermann J; Recke A; Zillikens D; Schmidt E; Probst C
Exp Dermatol; 2014 Apr; 23(4):253-9. PubMed ID: 24533885
[TBL] [Abstract][Full Text] [Related]
42. Autoantibody Levels and Clinical Disease Severity in Patients with Pemphigus: Comparison of Aggregated Anti-desmoglein ELISA Values and Indirect Immunofluorescence Titres.
Weiss D; Ristl R; Griss J; Bangert C; Foedinger D; Stingl G; Brunner PM
Acta Derm Venereol; 2015 May; 95(5):559-64. PubMed ID: 25423997
[TBL] [Abstract][Full Text] [Related]
43. In vitro keratinocyte dissociation assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in pemphigus vulgaris.
Ishii K; Harada R; Matsuo I; Shirakata Y; Hashimoto K; Amagai M
J Invest Dermatol; 2005 May; 124(5):939-46. PubMed ID: 15854034
[TBL] [Abstract][Full Text] [Related]
44. Immunofluorescence and immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera with desmoglein 3 and desmoglein 1.
Hashimoto T; Amagai M; Garrod DR; Nishikawa T
Epithelial Cell Biol; 1995; 4(2):63-9. PubMed ID: 8688919
[TBL] [Abstract][Full Text] [Related]
45. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile.
Amagai M; Tsunoda K; Zillikens D; Nagai T; Nishikawa T
J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):167-70. PubMed ID: 10025740
[TBL] [Abstract][Full Text] [Related]
46. Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission.
Daneshpazhooh M; Zafarmand Sedigh V; Balighi K; Hosseini SH; Ramezani A; Kalantari MS; Ghandi N; Ghiasi M; Nikoo A; Chams-Davatchi C
J Am Acad Dermatol; 2016 Jun; 74(6):1160-5. PubMed ID: 26896293
[TBL] [Abstract][Full Text] [Related]
47. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score.
Rahbar Z; Daneshpazhooh M; Mirshams-Shahshahani M; Esmaili N; Heidari K; Aghazadeh N; Hejazi P; Ghajarzadeh M; Chams-Davatchi C
JAMA Dermatol; 2014 Mar; 150(3):266-72. PubMed ID: 24429657
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of the pathogenicity of anti-desmoglein antibodies of pemphigus vulgaris patients using human organ culture assay.
Saleh AM; El-Samanoudy SI; Rashed LA; Saleh MA
Arch Dermatol Res; 2020 May; 312(4):289-294. PubMed ID: 31587106
[TBL] [Abstract][Full Text] [Related]
49. T lymphocytes from a subset of patients with pemphigus vulgaris respond to both desmoglein-3 and desmoglein-1.
Lin MS; Swartz SJ; Lopez A; Ding X; Fairley JA; Diaz LA
J Invest Dermatol; 1997 Dec; 109(6):734-7. PubMed ID: 9406813
[TBL] [Abstract][Full Text] [Related]
50. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3.
Nagel A; Lang A; Engel D; Podstawa E; Hunzelmann N; de Pita O; Borradori L; Uter W; Hertl M
Clin Immunol; 2010 Mar; 134(3):320-30. PubMed ID: 20015693
[TBL] [Abstract][Full Text] [Related]
51. Nuclear magnetic resonance titration of the interaction between pemphigus vulgaris autoantibodies and REWVKFAKPCRE, a therapeutic desmoglein 3 peptide.
Lucchese A; Sinha AA
Clin Exp Dermatol; 2016 Aug; 41(6):585-90. PubMed ID: 26936204
[TBL] [Abstract][Full Text] [Related]
52. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus.
Abasq C; Mouquet H; Gilbert D; Tron F; Grassi V; Musette P; Joly P
Arch Dermatol; 2009 May; 145(5):529-35. PubMed ID: 19451496
[TBL] [Abstract][Full Text] [Related]
53. Orodigital pemphigus vulgaris: a pathogenic role of anti-desmoglein-3 autoantibodies in pemphigus paronychia?
Laffitte E; Panizzon RG; Borradori L
Dermatology; 2008; 217(4):337-9. PubMed ID: 18799879
[TBL] [Abstract][Full Text] [Related]
54. Using desmoglein 1 and 3 enzyme-linked immunosorbent assay as an adjunct diagnostic tool for pemphigus.
Huang CH; Chen CC; Wang CJ; Chang YT; Liu HN
J Chin Med Assoc; 2007 Feb; 70(2):65-70. PubMed ID: 17339147
[TBL] [Abstract][Full Text] [Related]
55. Clues to diagnosis for unusual mucosal pemphigus demonstrating undetectable anti-desmoglein 3 serum antibodies by routine tests.
Kamiya K; Aoyama Y; Yamaguchi M; Ukida A; Mizuno-Ikeda K; Fujii K; Hamada T; Tokura Y; Iwatsuki K
J Dermatol; 2015 Jun; 42(6):572-9. PubMed ID: 25832452
[TBL] [Abstract][Full Text] [Related]
56. In vitro pathogenicity assay for anti-desmoglein autoantibodies in pemphigus.
Ishii K; Amagai M
Methods Mol Biol; 2013; 961():219-25. PubMed ID: 23325646
[TBL] [Abstract][Full Text] [Related]
57. Immune response in pemphigus and beyond: progresses and emerging concepts.
Di Zenzo G; Amber KT; Sayar BS; Müller EJ; Borradori L
Semin Immunopathol; 2016 Jan; 38(1):57-74. PubMed ID: 26597100
[TBL] [Abstract][Full Text] [Related]
58. Correlation of antimuscarinic acetylcholine receptor antibody titers and antidesmoglein antibody titers with the severity of disease in patients with pemphigus.
Lakshmi MJD; Jaisankar TJ; Rajappa M; Thappa DM; Chandrashekar L; Divyapriya D; Munisamy M; Revathy G
J Am Acad Dermatol; 2017 May; 76(5):895-902. PubMed ID: 28089115
[TBL] [Abstract][Full Text] [Related]
59. IgG autoantibodies directed against desmoglein 3 cause dissociation of keratinocytes in canine pemphigus vulgaris and paraneoplastic pemphigus.
Nishifuji K; Olivry T; Ishii K; Iwasaki T; Amagai M
Vet Immunol Immunopathol; 2007 Jun; 117(3-4):209-21. PubMed ID: 17350107
[TBL] [Abstract][Full Text] [Related]
60. Epitope analysis of antidesmoglein 1 autoantibodies from patients with pemphigus foliaceus across different activity stages.
Kamiya K; Aoyama Y; Yamasaki O; Kamata A; Yamagami J; Iwatsuki K; Tokura Y
Br J Dermatol; 2016 Jan; 174(1):113-9. PubMed ID: 26294113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
